Symbiotec Pharmalab IPO: Rs 1,757 Cr Issue Opens Aug 24

Symbiotec Pharmalab Limited is set to launch its Initial Public Offering (IPO) on August 24, 2026, aiming to raise Rs. 1,757 crore. The subscription window will close on August 27, 2026, with shares expected to list on the NSE and BSE by September 1, 2026.

The IPO includes a fresh issue of 0.15 crore equity shares, totaling Rs. 150 crore, alongside an Offer for Sale (OFS) of 1.63 crore shares worth Rs. 1,607 crore. Shares are priced between Rs. 938 and Rs. 988.

Key IPO Figures

• Total IPO Size: Rs. 1,757 crore
• Fresh Issue Value: Rs. 150 crore
• Offer for Sale Value: Rs. 1,607 crore
• Price Band: Rs. 938 to Rs. 988 per share
• Grey Market Premium (GMP) as of August 21, 2026: 32.39%
• GMP Share Price: Rs. 1,308 (a premium of Rs. 320 over the cap price)

Symbiotec Pharmalab, incorporated in 2002, specializes in developing and manufacturing active pharmaceutical ingredients (APIs), nutritional ingredients, and specialty products. The company boasts over 30 years of industry experience, serving both domestic and international markets.

OFS Participants & Utilisation

The Offer for Sale involves significant contributions from multiple entities. Symbiotec Pharmalab will not receive any proceeds from this component of the IPO.

• Satwani Holdings LLP: Rs. 144 crore
• Rosewood Investments: Rs. 988 crore
• India Business Excellence Fund–III: Rs. 475 crore

Proceeds from the fresh issue are designated for specific purposes. Up to Rs. 112.50 crore will go towards repaying or prepaying outstanding borrowings, with the remainder allocated for general corporate needs. This debt reduction is anticipated to lower finance costs and enhance financial flexibility for the company.

Financial Performance Highlights

The company has shown consistent financial growth leading up to the IPO. Its revenue and profitability metrics indicate a strengthening position.

• Revenue from operations (FY24 to FY26): Increased from Rs. 716.25 crore to Rs. 869.15 crore
• Profit After Tax (PAT) in FY26: Rs. 109.90 crore (13.55% growth after FY25)
• EBITDA in FY26: Rs. 231.97 crore (26.59% margin)
• PAT Margin in FY26: 12.60%
• Debt-to-Equity Ratio (FY25 to FY26): Improved from 0.64x to 0.33x
• Net Worth in FY26: Rs. 1,158.64 crore

Symbiotec Pharmalab operates two industrial-scale API manufacturing facilities as of June 30, 2025. The company holds key regulatory approvals, including from the US FDA, EU-GMP, and the Ministry of Food and Drug Safety, Korea.